59 studies found for:    St. Joseph Hospital AND Orange AND CA | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes
Interventions: Drug: lenalidomide;   Biological: epoetin alfa;   Other: laboratory biomarker analysis
22 Recruiting Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Recurrent Adult Brain Tumor
Interventions: Biological: anti-endoglin monoclonal antibody TRC105;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: quality-of-life assessment
23 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: docetaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
24 Recruiting S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
Interventions: Drug: FOLFOX regimen;   Drug: docetaxel;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
25 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
26 Recruiting Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: docetaxel;   Drug: carboplatin;   Biological: trastuzumab;   Biological: pertuzumab;   Drug: goserelin acetate;   Procedure: therapeutic conventional surgery;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis;   Drug: aromatase inhibition therapy;   Other: quality-of-life assessment
27 Recruiting Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Behavioral: behavioral dietary intervention;   Behavioral: exercise intervention;   Other: counseling intervention;   Other: educational intervention;   Behavioral: compliance monitoring;   Other: questionnaire administration;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
28 Recruiting S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Conditions: brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer
Interventions: Dietary Supplement: cholecalciferol;   Other: placebo
29 Recruiting Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma
Condition: Melanoma
Interventions: Drug: LGX818;   Drug: LGX818+MEK162;   Drug: vemurafenib
30 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweats, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Changes
Interventions: Drug: ibrutinib;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
31 Recruiting Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Conditions: Light Chain Deposition Disease;   Smoldering Multiple Myeloma
Interventions: Drug: lenalidomide;   Other: clinical observation;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
32 Recruiting Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Tumors Metastatic to Brain
Interventions: Drug: lapatinib ditosylate;   Radiation: whole-brain radiation therapy
33 Recruiting Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Conditions: Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Childhood Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Stage C Adult Primary Liver Cancer (BCLC);   Stage D Adult Primary Liver Cancer (BCLC);   Stage II Gallbladder Cancer;   Stage III Childhood Liver Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Childhood Liver Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: trametinib;   Drug: leucovorin calcium;   Drug: fluorouracil;   Drug: capecitabine;   Other: laboratory biomarker analysis
34 Recruiting Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Conditions: Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
35 Recruiting S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
36 Recruiting Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: dabrafenib;   Drug: trametinib;   Other: laboratory biomarker analysis
37 Recruiting Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Conditions: Childhood Hepatoblastoma;   Stage I Childhood Liver Cancer;   Stage II Childhood Liver Cancer;   Stage III Childhood Liver Cancer;   Stage IV Childhood Liver Cancer
Interventions: Procedure: therapeutic conventional surgery;   Drug: cisplatin;   Drug: fluorouracil;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: irinotecan hydrochloride;   Drug: temsirolimus;   Procedure: liver transplantation;   Other: laboratory biomarker analysis
38 Recruiting Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Conditions: Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: crizotinib;   Drug: dexamethasone;   Drug: ifosfamide;   Drug: methotrexate;   Drug: cytarabine;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis
39 Recruiting Neuropsychological and Behavioral Testing in Younger Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity;   Childhood Cancer;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity
Interventions: Procedure: psychosocial assessment and care;   Procedure: cognitive assessment;   Other: quality-of-life assessment;   Other: questionnaire administration
40 Recruiting Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Conditions: Disseminated Neuroblastoma;   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-59) Show next page of results    Last Page
Indicates status has not been verified in more than two years